Every day researchers work towards finding new breakthroughs in cancer. Clinical trials play a pivotal role in bringing that defeat closer.
Clinical trials test promising new treatments on people to see if they are better than existing cancer treatments. The trial process is long starting many years before an actual treatment can be used.
By joining a clinical trial you are helping to create new breakthroughs in cancer research. Hundreds of thousands of people all over the world have taken part in clinical trials that have lead to safer and more effective treatments for many cancers.
It is important to note that not all cancer patients are eligible to take part in clinical trials and there are not clinical trials for all types of cancer.
You may decide to join a clinical trial because:
- The treatment you receive will be at least the best available for your illness.
- Your health may improve because of the treatment you receive.
- You may receive a treatment you would not otherwise have access to.
- Your health will be carefully checked by the treatment team running the trial.
- You will be part of the worldwide effort to improve cancer treatment.
For more information on clinical trials please click here.
If you would like information regarding any of the below clinical trials, please contact the appropriate Clinical trials manager:
Ashford Cancer Centre: Helen Daykin, +61 8 8292 2240
Flinders Medical Centre: Alex Scott-Hoy, +61 8 8204 4830
The Queen Elizabeth: Sue Yeend, +61 8 8222 6148
Lyell McEwin Hospitals: Julie Rowe or Rohit Joshi +61 8 8282 0833
Royal Adelaide Hospital: Anne Milton, +61 8 7074 2342
Current clinical trials for other cancer
|Recruiting||15.03 (Fastrack II) Focal Ablative STereotactic RAdiosurgery for Cancers of the Kidney - A Phase II Clinical Trial||Royal Adelaide Hospital|
|Not yet recruiting||ACTICCA-1 Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gall bladder carcinoma||Flinders Medical Centre|
|Recruiting||ARRAY BEACON Multicenter, Randomized, Open-label, 3-Arm Phase 3 Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5- Fluorouracil (5-FU)/Folinic Acid (FA) /Irinotecan (FOLFIRI)/Cetuximab with a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients with BRAF V600E- mutant Metastatic Colorectal Cancer||Flinders Medical Centre|
|Recruiting||Phase I open label trial of Abraxane (nab-paclitaxel) administered concurrently with Radiotherapy in patients with locally advanced inoperable pancreatic adenocarcinoma||Flinders Medical Centre|
|Recruiting||BGB A317 BeiGene's Phase 1, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Antitumor Activities of the anti-PD-1Monoclonal Antibody BGB-A317 in Subjects with Advanced Tumors||Royal Adelaide Hospital|
|Recruiting||BGB-A317_Study_001 A Phase 1, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Antitumor Activities of the anti-PD-1 Monoclonal Antibody BGB-A317 in Subjects with Advanced Tumors||The Queen Elizabeth Hospital|
|Now closed||A MULTICENTRE RANDOMIZED PHASE II TRIAL COMPARING NAB-PACLITAXEL TO PACLITAXEL IN PATIENTS WITH ADVANCED UROTHELIAL CANCER PROGRESSING ON OR AFTER A PLATINUM CONTAINING REGIMEN||Flinders Medical Centre|
|Recruiting||CA209-577 Randomized, Multicenter, Double blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction cancer.||Royal Adelaide Hospital|
|Not yet recruiting||CANSTEM BBI608 A Phase III Study of BBI-608 in combination with 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients with Previously Treated Metastatic Colorectal Cancer (CRC).||Flinders Medical Centre|
|Recruiting||ELD15 - An international field study of the reliability and vailidity of an eortc older-specific quality of life (QOL) questionnaire module (the eortc QLQ-ELD15) and eortc QLQ-C30 in assessing the QOL of cancer patients aged 70 years and above||Royal Adelaide Hospital|
|Recruiting||EMR200647‐001 A Phase I, open‐label, multiple‐ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications||The Queen Elizabeth Hospital|
|Recruiting||FIG Efficacy and safety of FOLFIRINOX as Neoadjuvant chemotherapy for resectable gastric or gastroesophageal junction adenocarcinoma: A Run-In Pilot followed by Phase 2 comparison between ECF and FOLFIRINOX – FIG Study||Royal Adelaide Hospital|
|Not yet recruiting||GLANCE Global Treatment Patterns, Health Care Resource Utilization, and Survival Outcomes among Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck||Flinders Medical Centre|
|Recruiting||HPV Oropharynx A Randomised Trial of Weekly Cetuximab and 408.14 1 Radiation versus Weekly Cisplatin and Radiation in Good Prognosis Locoregionally Advanced HPV-Associated Oropharyngeal Squamous Cell Carcinoma (HPV OROPHARYNX)||Flinders Medical Centre|
|Recruiting||InterAACT An International Multicentre Open Label Randomised Phase II Advanced Anal Cancer Trial Comparing Cisplatin plus 5-fluorouracil versus Carboplatin plus Weekly Paclitaxel in Patients with Inoperable Locally Recurrent or Metastatic Disease||Flinders Medical Centre|
|Recruiting||Randomised, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib or Placebo plus Cisplatin and Gemcitabine as First-line treatment in patients with Advanced or metastatic Biliary Tract Cancer||Royal Adelaide Hospital|
|Recruiting||Keynote -522 A Phase III randomized, double-blind study to evaluate Pembrolizumab plus chemotherapy vs placebo plus chemotherapy as neoadjuvant therapy and pembrolizumab vs placebo as adjuvant therapy for TNBC||Royal Adelaide Hospital|
|Recruiting||A Randomised Phase III study of pembrolizumab given concomitantly with chemoradiation and as maintenance therapy versus chemoradiation alone in subjects with locally advanced H&N SCC.||Royal Adelaide Hospital|
|Recruiting||NIMO - Phase 2, double-blind, placebo-controlled study of post-operative adjuvant concurrent chemo-radiotherapy with or without nimotuzumab for stage 3 or 4 head and neck squamous cell cancer||Flinders Medical Centre|
|Recruiting||QB46C-H02. Phase I Dose-Escalation Study to determine the Safety and Tolerability of an Intratumoural Injection of EBC-46 in Patients with Refractory Cutaneous or Subcutaneous Tumours||Flinders Medical Centre|
|Not yet Recruiting||S-AVANT S-AVANT C13-1 Follow up to the AVANT study at 8 and 10 years (median follow-up in patients with carcinoma||Flinders Medical Centre|
|Recruiting||SPIT - Saliva used as a prognostic indicator in treatment||Flinders Medical Centre|
|Recruiting||XL184-401 A Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Cabozantinib (XL184) at 60mg/Day Compared to 140mg/Day in Progressive, Metastatic Medullary Thyroid Cancer Patients||Ashford Cancer Centre Research|